Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 1/20 | 0.64 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.45 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.44 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.44 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.44 |
| ▸ | DPP7 | Q9UHL4 | 9/20 | 0.43 |
| ▸ | DPP9 | Q86TI2 | 6/20 | 0.43 |
| ▸ | DPP8 | Q6V1X1 | 5/20 | 0.43 |
| ▸ | DPP4 | P27487 | 3/20 | 0.43 |
| ▸ | FAP | Q12884 | 1/20 | 0.42 |
| ▸ | MMP2 | P08253 | 1/20 | 0.41 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29595628 | 1.00 | GSR (0.64) | GSRRNPEPGNAI3GNAO1GNAI1 | |
| SCHEMBL28486930 | 0.93 | — | — | |
| SCHEMBL29707222 | 0.93 | — | — | |
| SCHEMBL28486931 | 0.93 | — | — | |
| Fluoride SCHEMBL28990878 | 0.91 | GSR (0.52) | GSRRNPEPGNAI3GNAO1GNAI1 | |
| SCHEMBL29803185 | 0.82 | — | — | |
| SCHEMBL16272838 | 0.82 | — | — | |
| Lysine SCHEMBL28127136 | 0.80 | GSR (0.83) | GSRRNPEPCPB2 | |
| SCHEMBL9915164 | 0.80 | GSR (0.70) | GSRRNPEPGNAI3GNAO1GNAI1 | |
| SCHEMBL18691832 | 0.78 | GSR (0.67) | GSRRNPEPGNAI3GNAO1GNAI1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250304624-A1 | CONJUGATED HEPCIDIN MIMETICS | PROTAGONIST THERAPEUTICS, INC. | 2025-10-02 | — | — | US | disclosed |
| US-12234300-B2 | Conjugated hepcidin mimetics | PROTAGONIST THERAPEUTICS, INC. (US) | 2025-02-25 | — | — | US | disclosed |
| US-20240209024-A1 | CONJUGATED HEPCIDIN MIMETICS | PROTAGONIST THERAPEUTICS, INC. | 2024-06-27 | — | — | US | disclosed |
| US-11753443-B2 | Conjugated hepcidin mimetics | PROTAGONIST THERAPEUTICS, INC. (US) | 2023-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240209024-A1 | CONJUGATED HEPCIDIN MIMETICS | HAMP, VIP, HDGF | GSR 2345/4885RNPEP 223/4885GNAI3 2385/4885 |
| US-12234300-B2 | Conjugated hepcidin mimetics | HAMP, VIP, HDGF | GSR 2345/4885RNPEP 223/4885GNAI3 2385/4885 |
| US-11753443-B2 | Conjugated hepcidin mimetics | HAMP, VIP, HDGF | GSR 2345/4885RNPEP 223/4885GNAI3 2385/4885 |
| US-20250304624-A1 | CONJUGATED HEPCIDIN MIMETICS | HAMP, VIP, HDGF | GSR 2345/4885RNPEP 223/4885GNAI3 2385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.